Shares of Evotec took a nasty hit after Hyperion ($HPTX) alleged that it had been duped by fraudulent data on the diabetes drug DiaPep277, which was in-licensed from Israel's Andromeda Biotech. Now Evotec, which had lined up rights to the drug in an earlier deal, wants some payback. The German biotech says it will take legal action against Andromeda for the damages that have resulted. And this dust-up has only just begun. More litigation is all but guaranteed. Release